Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.

Rod Ramchandren,David J Straus,Nancy L Bartlett,Andres Forero-Torres,Anas Younes,Ajay K Gopal,Stephen M Ansell,Gerald Engley,Leo I Gordon,Kerry J Savage,Robert W Chen,Tatyana Feldman,Thomas John Manley,John Kuruvilla,Joseph M Connors,Ranjana H Advani,Keenan Fenton,Jonathan W Friedberg

doi:10.1200/jco.2018.36.15_suppl.7541

Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.

Rod Ramchandren, David J Straus + Show 16 more

https://doi.org/10.1200/jco.2018.36.15_suppl.7541

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2018
Citations: 4

Affiliation: Karmanos Cancer Institute, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, University of Alabama at Birmingham, University of Washington Medical Center, Mayo Clinic, MED Institute, College Station Medical Center, Northwestern University, BC Cancer Agency, City Of Hope National Medical Center, Hackensack University Medical Center, Seagen (United States), Princess Margaret Cancer Centre, Cancer Prevention Institute of California, University of Rochester

#Brentuximab Vedotin #Hodgkin Lymphoma + Show 4 more

Abstract
Full-Text PDF
Similar Papers

Abstract

7541Background: ECHELON-1 is a global, phase 3 study of BV plus doxorubicin, vinblastine, and dacarbazine (A+AVD) vs ABVD as frontline therapy in patients with advanced HL (NCT01712490). The primar...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.